Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2023 07:06 ET | Source: Oculis SA

Oculis Announces Launch of Proposed Public Offering of Ordinary Shares

ZUG, Switzerland and BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
May 24, 2023 08:00 ET | Source: Oculis SA

Oculis to Participate and Present at Upcoming EuDES Meeting

ZUG, Switzerland and BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
May 22, 2023 06:30 ET | Source: Oculis SA

Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops

DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with...
May 11, 2023 08:00 ET | Source: Oculis SA

Oculis Co-founders Selected as Finalists in European Inventor Award 2023

Professors Einar Stefánsson and Thorsteinn Loftsson, Oculis’ co-founders, nominated in ‘Research’ category of prestigious European Patent Office awardsNominated in recognition of research developing...
April 26, 2023 07:00 ET | Source: Oculis SA

Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs

Oculis establishes its US headquarters in Boston, MA, a world-renowned biotech hub, to support its continued expansion following OCS listing into NASDAQ Oculis’s finance and development team...
April 05, 2023 07:00 ET | Source: Oculis SA

Oculis to Participate at Upcoming Investor Conferences

ZUG, Switzerland and BOSTON, April 05, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
April 04, 2023 07:00 ET | Source: Oculis SA

Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
March 22, 2023 07:00 ET | Source: Oculis SA

Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing

ZUG, Switzerland, and BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...
March 16, 2023 09:45 ET | Source: Oculis SA

Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial

Completed enrollment in Phase 3 OPTIMIZE trial brings OCS-01 one step further on the regulatory path to approval.If approved, OCS-01 has the potential to become the first once-daily, topical,...
September 01, 2020 08:00 ET | Source: Oculis SA

Oculis establishes presence in U.S. and appoints Sylvia Cheung as Chief Financial Officer

LAUSANNE, Switzerland, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives...